Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Eisai
Woman and Man Max 99 years
Eisai Inc
Update Il y a 5 ans
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Dacarbazine versus Dacarbazine Alone as First Line Therapy in Patients with Stage IV Melanoma
• Phase Ib: to define the safety, tolerability and maximum tolerated dose (MTD) of E7080 administered in combination with dacarbazine in patients with Stage IV melanoma. • Phase II: to evaluate the ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 5 ans
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease Estudio de 24 meses, de grupos paralelos, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de E2609 en pacientes con enfermedad de Alzheimer temprana
To determine whether elenbecestat (E2609) is superior to placebo on the change from baseline in the Clinical Dementia Rating - Sum Of Boxes (CDR-SB) at 24 months in subjects with Early Alzheimer’s Dis...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 5 ans
A controlled clinical trial to look at the effects of treatment with rufinamide on the body, thought process development and its safety in children aged 1 to 4 years with poorly controlled Lennox Gastaut Syndrome
To compare the effect of 2 drug regimens consisting of either rufinamide or any other approved AED of the investigator’s choice as an add-on to the subject’s existing regimen of 1-3 AEDs on the overal...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 5 ans
A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations
To evaluate the long-term safety and tolerability of E2007 in subjects with Parkinson’s disease (PD) who experience end-of-dose “wearing-off” motor fluctuations
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 5 ans
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial seizures
The primary objective is to evaluate the safety and tolerability of perampanel (up to12mg/day) given as adjunctive treatment in subjects with refractory partial seizures
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Eisai Medical Research Inc.
Update Il y a 5 ans
MORAb003-004 : Essai de phase 3 randomisé évaluant l’efficacité et la tolérance du farletuzumab associé à du carboplatine et du taxane, chez des patientes ayant un cancer de l’ovaire sensible au platine en rechute. [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité de deux doses de farletuzumab associées à une chimiothérapie standard, chez des patientes ayant un cancer de l’ovaire en rechute. Les patientes se...
Country
France
organs
Ovaire
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 5 ans
A Study on the Effect of E5501 (study drug) in Subjects with Chronic Hepatitis C Virus (HCV)-related Thrombocytopenia who are Potential Candidates for Antiviral Treatment
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 6 years and 18 years
Eisai
Update Il y a 5 ans
Étude BOLD : étude de phase 1-2 évaluant la sécurité, la tolérance et l'efficacité du mésylate d'éribuline associé à de l’irinotecan chez des enfants ayants des tumeurs solides récurrentes ou réfractaires.
Les sarcomes représentent environ 6 % de l’ensemble des tumeurs malignes chez l’enfant et l’adolescent. Le type histologique le plus fréquent chez l’enfant est le rhabdomyosarcome qui représente envir...
Country
France
organs
Tumeurs solides
,
Sarcomes
Specialty
Chimiothérapie
,
Pédiatrie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 5 ans
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Disease (GERD)
To compare efficacy (i.e. healing and symptom relief) of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg after 4-8 weeks of treatment among subjects with erosive GERD (eG...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 5 ans
Lemborexant for long-term treatment of insomnia disorder in adults Lemborexant para el tratamiento a largo plazo del insomnio en adultos
Determine the efficacy of lemborexant 5 mg (LEM5) and 10 mg (LEM10) compared to placebo (PBO) on subjective sleep onset latency (sSOL) after 6 months of treatment in subjects with insomnia disorder ...
Country
None
organs
None
Specialty
None
unknown
More information
1
2
3
4
5
6
7
8
9
Next